Journals / Medeniyet Medical Journal / 2020 / Cilt: 35 - Sayı: 3

Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor

SARS-CoV-2 Spike Glikoproteininde Saptanan Mutasyonlar ve Bunların Virüsün ACE-2 Reseptörle Etkileşimine Etkileri

Pages
253–260
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, information about the mutations observed in the SARS-CoV-2 S glycoproteinand their possible effects are presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronaviruses (CoVs) classified in the Coronaviridae family infect a very large spectrum of vertebrate group.
📊
Key Findings & Data:Seven CoVs that cause human disease consist of Alpha-CoVs, which are HCoV229E, and NL63 and beta-CoVs, which are MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1,and SARS-CoV-2.
💡
Conclusion & Impact:In this article, information about the mutations observed in the SARS-CoV-2 S glycoproteinand their possible effects are presented.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Coronaviruses (CoVs) classified in the Coronaviridae family infect a very large spectrum of vertebrate group. Seven CoVs that cause human disease consist of Alpha-CoVs, which are HCoV229E, and NL63 and beta-CoVs, which are MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1,and SARS-CoV-2. SARS-CoV-2 is an enveloped, positive-polarity, single-stranded RNA virusresponsible for a new Coronavirus disease 2019 (COVID-19). The mutagenic ability of the SARSCoV-2 directs its evolution and genome variability, thus allowing viruses to escape from hostimmunity and develop drug resistance. Tracing viral mutations is also important for the development of new vaccines, antiviral drugs, and diagnostic systems. During replication in the host cell,genomic mutations occur in the virus and these mutations are transferred to new generations.For this reason, systematic monitoring of mutations in the SARS-CoV-2 genome allows observation of the national and international molecular epidemiology of the virus. SARS-CoV-2 spike(S) glycoprotein is vital in the binding of the virus to the host cell receptor that is angiotensinconverting-enzyme 2 (ACE2), membrane fusion, vaccine studies and immune response to thevirus. Therefore, mutations in the gene encoding the S glycoprotein and especially the possiblevariations in the receptor binding domain (RBD) in S gene are important issues to be emphasized. In this article, information about the mutations observed in the SARS-CoV-2 S glycoproteinand their possible effects are presented.

Özet

Coronaviridae familyası içerisinde sınıflandırılan koronavirüsler (CoVs) oldukça geniş bir omurgalı grubu enfekte etmektedir. İnsanlarda hastalık oluşturan yedi tip koronavirüsten HCoV-229E ve NL63 alfa, MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1, SARS-CoV-2 ise beta cinsinde yer almaktadır. SARS-CoV-2, yeni bir koronavirüs hastalığına (Coronavirus disease 2019; COVID-19) yol açan zarflı, pozitif-polariteli, tek sarmallı bir RNA virüsüdür. SARS-CoV-2’nin mutasyon kabiliyeti viral evrimi ve genom değişkenliğini yönlendirir. Böylece virüslerin konakçı bağışıklığından kaçmasına ve ilaç direnci geliştirmesine olanak tanır. Ayrıca viral mutasyonların izlenmesi yeni aşılar, anti-viral ilaçlar ve tanı sistemlerinin geliştirilmesi için de önemlidir. Konak hücrede replikasyon esnasında virüste mutasyon oluşmakta ve bu mutasyonlar yeni soylara aktarılmaktadır. Bu nedenle SARS-CoV-2 genomundaki mutasyonların sistematik bir biçimde izlenmesi virüsün ulusal ve uluslararası moleküler epidemiyolojisinin gözlenmesine olanak sağlamaktadır. SARSCoV-2’nin spike (S) proteini virüsün konak hücre reseptörü olan anjiyotensin dönüştürücü enzim 2’ye (ACE2) bağlanması, membrana füzyonu, aşı çalışmaları ve oluşacak bağışık yanıtta hayati öneme sahiptir. Bu nedenle S glikoproteinini kodlayan gendeki mutasyonlar ve özellikle virüsün ACE-2 reseptörüne bağlanma bölgesindeki (RBD olası varyasyonların irdelenmesi, üzerinde durulması gereken önemli konulardandır. Bu yazıda SARS-CoV-2 S glikoproteininde saptanmış olan mutasyonlar ve olası etkileri hakkında bilgi sunulmuştur

🔖

Cite This Article

DURMAZ, B., ABDULMAJED, O., DURMAZ, R. (2022). Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor. Medeniyet Medical Journal, Cilt: 35 - Sayı: 3, 253–260. https://ajindex.com/articles/579210

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Center for disease control and prevention. Human Coronavirus types. Available from:https://www.cdc.gov/coronavirus/types.html. Accessed date: June 15, 2020
  2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. [CrossRef] 3. Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020;109:102434. [CrossRef] 4. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727-32. [CrossRef] 5. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69. [CrossRef] 6. Ho W, Huang Y, Jin D-Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet. 2020;395:949-50. [CrossRef] 7. Worldmeters. COVID-19 Coronavirus pandemic. 2020. Available from: https://www.worldometers.info/coronavirus/. Accessed date: June 15, 2020
  3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID19)-China. Chin J Epidemiol. 2020;41:145-51
  4. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. [CrossRef] 10. T.C. Ministry of Health. COVID-19 (SARS-CoV-2 Infection) General Information, Epidemiology and Diagnosis. 2020. Accessed date: June 15 2020
  5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. [CrossRef] 12. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323:1406-7. [CrossRef] 13. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565. [CrossRef] 14. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. J Med Virol. 2020;92:522-8. [CrossRef] 15. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69. [CrossRef] 16. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020. [CrossRef] 17. Li X, Geng M, Peng Y, Meng